VIA
NKTR icon

Vident Investment Advisory’s Nektar Therapeutics NKTR Stock Holding History

Vident Investment Advisory’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,247
Closed -$34.1K – 1300
2023
Q1 		$34.1K Buy
3,247
+56
+2% +$1.69K ﹤0.01% 1217
2022
Q4 		$108K Sell
3,191
-11,097
-78% -$537K ﹤0.01% 1098
2022
Q3 		$679K Sell
14,288
-1,073
-7% -$63.8K 0.02% 694
2022
Q2 		$875K Buy
15,361
+8,918
+138% +$563K 0.03% 665
2022
Q1 		$521K Buy
6,443
+833
+15% +$123K 0.01% 917
2021
Q4 		$1.14M Sell
5,610
-42
-0.7% -$9.11K 0.03% 653
2021
Q3 		$1.52M Sell
5,652
-1,028
-15% -$247K 0.05% 546
2021
Q2 		$1.72M Sell
6,680
-34
-0.5% -$9.41K 0.05% 470
2021
Q1 		$2.02M Buy
6,714
+42
+0.6% +$13.1K 0.07% 372
2020
Q4 		$1.7M Buy
6,672
+2,455
+58% +$634K 0.07% 348
2020
Q3 		$1.05M Sell
4,217
-599
-12% -$188K 0.05% 474
2020
Q2 		$1.67M Buy
4,816
+108
+2% +$33.7K 0.09% 256
2020
Q1 		$1.26M Sell
4,708
-3,616
-43% -$1.12M 0.08% 310
2019
Q4 		$2.69M Buy
8,324
+5,556
+201% +$1.61M 0.17% 148
2019
Q3 		$756K Sell
2,768
-1,017
-27% -$373K 0.07% 224
2019
Q2 		$2.02M Sell
3,785
-3,585
-49% -$1.8M 0.16% 87
2019
Q1 		$3.71M Buy
7,370
+3,649
+98% +$2.16M 0.2% 88
2018
Q4 		$1.83M Sell
3,721
-28
-0.7% -$16.9K 0.1% 274
2018
Q3 		$3.43M Buy
3,749
+216
+6% +$184K 0.13% 183
2018
Q2 		$2.59M Buy
3,533
+1,176
+50% +$1.36M 0.1% 273
2018
Q1 		$3.19M Buy
2,357
+934
+66% +$1.2M 0.13% 212
2017
Q4 		$1.56M Buy
+1,423
New +$842K 0.07% 309

Other funds holding NKTR

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Vident Investment Advisory's NKTR Position: Q2 2023 in Review

Vident Investment Advisory sold out of Nektar Therapeutics (NKTR) in Q2 2023, closing a stake of 3,247 shares — an estimated $34.1K sold.

Vident Investment Advisory first reported a position in NKTR in Q4 2017 and held it in 22 quarters. The position peaked at $3.71M in Q1 2019. 146 funds tracked by Wall St. Rank hold NKTR as of Q2 2023.

  • Vident Investment Advisory reported no remaining Nektar Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 3,247 Nektar Therapeutics shares in Q2 2023, an estimated $34.1K.
  • Vident Investment Advisory first reported a position in Nektar Therapeutics in Q4 2017 and held it in 22 quarters.
  • Vident Investment Advisory's Nektar Therapeutics position peaked at $3.71M in Q1 2019.
  • 146 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2023.

Based on Vident Investment Advisory's 13F filing for Q2 2023, filed 11 Aug 2023.